Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Klaus J Nickisch"'
Autor:
Hareesh B Nair, Bindu Santhamma, Naveen K Krishnegowda, Kalarikkal V Dileep, Klaus J Nickisch
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151182 (2016)
Use of estrogen or estrogen/progestin combination was an approved regimen for menopausal hormonal therapy (MHT). However, more recent patient-centered studies revealed an increase in the incidence of breast cancer in women receiving menopausal hormon
Externí odkaz:
https://doaj.org/article/af532240aaac41fd840aff5c551d9b81
Autor:
Mengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, Uday P. Pratap, Yiliao Luo, Junhao Liu, Kristin A. Altwegg, Weiwei Tang, Zexuan Liu, Xiaonan Li, Behnam Ebrahimi, Hui Yan, Yi Zou, Swapna Konda, Gangadhara R. Sareddy, Zhenming Xu, Yidong Chen, Manjeet K. Rao, Andrew J. Brenner, Virginia G. Kaklamani, Rajeshwar R. Tekmal, Gulzar Ahmed, Ganesh V. Raj, Klaus J. Nickisch, Hareesh B. Nair, Ratna K. Vadlamudi
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Li, Viswanadhapalli et al utilized multiple in vitro, ex vivo and in vivo models of TNBC to investigate LIFR inhibition. The authors reported that HDAC inhibition in TNBC cells led to an increase of LIFR expression and over activation of the downstre
Externí odkaz:
https://doaj.org/article/8b39ff553a7a47e7a5a926087847574b
Autor:
Ratna K. Vadlamudi, Klaus J. Nickisch, Hareesh B. Nair, Rajeshwar R. Tekmal, Manjeet K. Rao, Vijaya Manthati, Andrew J. Brenner, Ganesh V. Raj, Marek Bajda, Ramachandran Murali, Xinlei Pan, Kam Y.J. Zhang, Kalarickal V. Dileep, Alejandra Chávez-Riveros, Annabel Chang, Xiaonan Li, Kristin A. Altwegg, Uday P. Pratap, Rajni Sonavane, Shihong Ma, Mengxing Li, Mei Zhou, Bindu Santhamma, Gangadhara R. Sareddy, Yiliao Luo, Suryavathi Viswanadhapalli
Leukemia inhibitory factor receptor (LIFR) and its ligand LIF play a critical role in cancer progression, metastasis, stem cell maintenance, and therapy resistance. Here, we describe a rationally designed first-in-class inhibitor of LIFR, EC359, whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e07cd43c1488eac97dde539175fac68e
https://doi.org/10.1158/1535-7163.c.6538359.v1
https://doi.org/10.1158/1535-7163.c.6538359.v1
Autor:
Ratna K. Vadlamudi, Klaus J. Nickisch, Hareesh B. Nair, Rajeshwar R. Tekmal, Manjeet K. Rao, Vijaya Manthati, Andrew J. Brenner, Ganesh V. Raj, Marek Bajda, Ramachandran Murali, Xinlei Pan, Kam Y.J. Zhang, Kalarickal V. Dileep, Alejandra Chávez-Riveros, Annabel Chang, Xiaonan Li, Kristin A. Altwegg, Uday P. Pratap, Rajni Sonavane, Shihong Ma, Mengxing Li, Mei Zhou, Bindu Santhamma, Gangadhara R. Sareddy, Yiliao Luo, Suryavathi Viswanadhapalli
Supplementary Figure S1 shows SPR studies and Biotin EC359 pull down assays; Supplementary Figure S2 shows superimposition of hLIFR onto the mLIFR -hLIF complex; Supplementary Figure S3 shows sequence alignment of human (P42702) and mouse (P42703) LI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ee451be075a9d46cb02b1970ab4b84
https://doi.org/10.1158/1535-7163.22506315
https://doi.org/10.1158/1535-7163.22506315
Autor:
Ratna K. Vadlamudi, Klaus J. Nickisch, Hareesh B. Nair, Rajeshwar R. Tekmal, Manjeet K. Rao, Vijaya Manthati, Andrew J. Brenner, Ganesh V. Raj, Marek Bajda, Ramachandran Murali, Xinlei Pan, Kam Y.J. Zhang, Kalarickal V. Dileep, Alejandra Chávez-Riveros, Annabel Chang, Xiaonan Li, Kristin A. Altwegg, Uday P. Pratap, Rajni Sonavane, Shihong Ma, Mengxing Li, Mei Zhou, Bindu Santhamma, Gangadhara R. Sareddy, Yiliao Luo, Suryavathi Viswanadhapalli
Supplementary methods section contain description of synthesis and characterization of EC330 and EC359, SPR studies, structural and sequence comparison of human and mouse LIFR, energy minimization of hLIFR, Protein and ligand preparation, molecular d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f80ccb9927594621014305b0b7429d
https://doi.org/10.1158/1535-7163.22506309.v1
https://doi.org/10.1158/1535-7163.22506309.v1
Autor:
Yiliao Luo, Hareesh B. Nair, Zhenming Xu, Hui Yan, Mengxing Li, Kristin A. Altwegg, Rajeshwar Rao Tekmal, Uday P. Pratap, Klaus J. Nickisch, Xiaonan Li, Bindu Santhamma, Junhao Liu, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Andrew Brenner, Ratna K. Vadlamudi
Publikováno v:
Cancer Research. 80:P3-11
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease. TNBC lacks targeted therapies and represents a disproportional share of the breast cancer (BC) mortality rate. Histone deacetylase inhibitors (HDACIs) are emerging as promis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e0c4ebbd1f5456f88b4e6eded1c4529
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-08
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-08
Autor:
Yiliao Luo, Hareesh B. Nair, Gulzar Ahmed, Mengxing Li, Weiwei Tang, Rajeshwar Rao Tekmal, Junhao Liu, Yi Zou, Zexuan Liu, Swapna Konda, Virginia G. Kaklamani, Xiaonan Li, Yi Chen, Gangadhara R. Sareddy, Hui Yan, Manjeet K. Rao, Ganesh V. Raj, Ratna K. Vadlamudi, Kristin A. Altwegg, Klaus J. Nickisch, Suryavathi Viswanadhapalli, Andrew Brenner, Behnam Ebrahimi, Zhenming Xu, Bindu Santhamma, Uday P. Pratap
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Communications Biology
Communications Biology
Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leuke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc12327f83bbf883fa78056ba141eb6
https://doi.org/10.1038/s42003-021-02741-7
https://doi.org/10.1038/s42003-021-02741-7
Autor:
Suryavathi Viswanadhapalli, Marek Bajda, Kam Y. J. Zhang, Ramachandran Murali, Manjeet K. Rao, Klaus J. Nickisch, Mengxing Li, Xiaonan Li, Ganesh V. Raj, Annabel Chang, Ratna K. Vadlamudi, Kalarickal V. Dileep, Shihong Ma, Kristin A. Altwegg, Rajni Sonavane, Vijaya Manthati, Mei Zhou, Yiliao Luo, Hareesh B. Nair, Xinlei Pan, Rajeshwar Rao Tekmal, Uday P. Pratap, Andrew Brenner, Alejandra Chavez-Riveros, Bindu Santhamma, Gangadhara R. Sareddy
Publikováno v:
Mol Cancer Ther
Leukemia inhibitory factor receptor (LIFR) and its ligand LIF play a critical role in cancer progression, metastasis, stem cell maintenance, and therapy resistance. Here, we describe a rationally designed first-in-class inhibitor of LIFR, EC359, whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c685d6bfed97cbde41d578e7a1ee80
https://doi.org/10.1158/1535-7163.mct-18-1258
https://doi.org/10.1158/1535-7163.mct-18-1258
Autor:
Manjeet K. Rao, Annabel Chang, Marek Bajda, Kristin A. Altwegg, Ramachandran Murali, Kalarickal V. Dileep, Mei Zhou, Vijaya Manthati, GR Sareddy, Xinlei Pan, Yiliao Luo, Kam Y. J. Zhang, Hareesh B. Nair, Uday P. Pratap, Xiaonan Li, Ganesh V. Raj, Mengxing Li, Andrew Brenner, U Srinivasan, RK Vadlamudi, Rajeshwar Rao Tekmal, Bindu Santhamma, Klaus J. Nickisch, S Ma, AC Riveros, Suryavathi Viswanadhapalli
Publikováno v:
Cancer Research. 79:P2-06
Background: Leukemia inhibitory factor (LIF) and its receptor LIFR are over-expressed in multiple solid tumors and play a key role in tumor growth, progression, and resistance to standard anti-cancer treatments. Triple-negative breast cancer (TNBC) l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13e933b56cff9779cec67a6f27a132e2
https://doi.org/10.1158/1538-7445.sabcs18-p2-06-02
https://doi.org/10.1158/1538-7445.sabcs18-p2-06-02
Autor:
Hareesh B. Nair, Michael A. Owston, Robert Baker, Klaus J. Nickisch, John L. VandeBerg, Renee Escalona, Edward J. Dick
Publikováno v:
Oncotarget
// Hareesh B. Nair 1 , Robert Baker 2 , Michael A. Owston 2 , Renee Escalona 2 , Edward J. Dick 2 , John L. VandeBerg 2 and Klaus J. Nickisch 1 1 Evestra, Inc., San Antonio, TX, USA 2 Southwest National Primate Research Center, Texas Biomedical Resea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ae694f51e9c122f215e9f7fe264c37
https://doi.org/10.18632/oncotarget.7516
https://doi.org/10.18632/oncotarget.7516